HIV virologic response, patterns of drug resistance mutations and correlates among adolescents and young adults: A cross-sectional study in Tanzania

The emergence of HIV drug resistance mutations (DRMs) is of significant threat to achieving viral suppression (VS) in the quest to achieve global elimination targets. We hereby report virologic outcomes and patterns of acquired DRMs and its associated factors among adolescents and young adults (AYA)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2023-02, Vol.18 (2), p.e0281528-e0281528
Hauptverfasser: Rugemalila, Joan, Kamori, Doreen, Kunambi, Peter, Mizinduko, Mucho, Sabasaba, Amon, Masoud, Salim, Msafiri, Frank, Mugusi, Sabina, Mutagonda, Rita, Mlunde, Linda, Amani, Davis, Mboya, Erick, Mahiti, Macdonald, Ruhago, George, Mushi, Jeremiah, Sambu, Veryeh, Mgomella, George, Jullu, Boniface, Maokola, Werner, Njau, Prosper, Mutayoba, Beatrice, Barabona, Godfrey, Ueno, Takamasa, Pembe, Andrea, Nagu, Tumaini, Sunguya, Bruno, Aboud, Said
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The emergence of HIV drug resistance mutations (DRMs) is of significant threat to achieving viral suppression (VS) in the quest to achieve global elimination targets. We hereby report virologic outcomes and patterns of acquired DRMs and its associated factors among adolescents and young adults (AYA) from a broader HIV drug resistance surveillance conducted in Tanzania. Data of AYA was extracted from a cross-sectional study conducted in 36 selected facilities using a two-stage cluster sampling design. Dried blood spot (DBS) samples were collected and samples with a viral load (VL) ≥1000 copies/mL underwent genotyping for the HIV-1 pol gene. Stanford HIV database algorithm predicted acquired DRMs, Fisher's exact test and multivariable logistic regression assessed factors associated with DRMs and VS, respectively. We analyzed data of 578 AYA on antiretroviral therapy (ART) for 9-15 and ≥ 36 months; among them, 91.5% and 88.2% had VS (VL
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0281528